Factors associated with the consumption of psychoactive substances in a group of patients diagnosed with schizophrenia from a mental health institution in Medellín, Antioquia
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: to establish the relationship between sociodemographic and clinical factors with the consumption of psychoactive substances (PAS) in a group of patients diagnosed with schizophrenia, treated at a mental health institution in the city of Medellín, Colombia.
Methodology: observational, retrospective study with analytical intent, of a group of 268 patients treated at a mental health institution in Medellín, in the last six months of 2021. Sociodemographic, SPA consumption, and clinical factors such as the type of medication, hospital readmissions and adherence to drug treatment were identified. Odds Ratio values with confidence interval (95% CI) were considered and factors associated with consumption were identified by means of a logistic regression model.
Results: it was shown that 34.7% of the sample reports PAS consumption, associated clinical variables, type of medication, number of hospital admissions, and adherence to treatment. Significant differences in age were found between the group of users and non-users, with a lower median age for the group of users. It was determined that being a man, having a median age of 27 years and being unemployed represent a greater risk for the consumption of PAS. Finally, it is established that age, sex, occupation, and adherence to treatment could predict consumption by 34%.
Conclusions: young patients, mostly men, with a diagnosis of schizophrenia, have a higher risk of PAS consumption, which implies a higher risk of relapse and lower adherence to drug treatment.
Article Details
References
Hany M, Rehman B, Azhar Y. Schizophrenia. [Actualizado 2021 Nov 27]. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Disponible en: https://www.ncbi.nlm.nih. gov/books/NBK539864/
Organización Mundial de la Salud. Esquizofrenia [Internet]. OMS; 2022 [consultado 2 mar 2022]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/schizophrenia
Morales, PA. Situación actual de los trastornos mentales en Colombia y en el mundo: prevalencia, consecuencias y necesidades de intervención. Rev Salud Bosque. 2016;6(2):29–40.
Osorio JH, Valencia G, Pérez JM. Evolución en el diagnóstico de la esquizofrenia en el departamento de Caldas, Colombia. 2010-2015. Rev la Fac Med. 2021;69(3):e73159–e73159.
Gómez DM, Hincapié C, Salas C, Cardona L, Castañeda A. Resultados del tamizaje en salud mental departamento de Antioquia 2009-2010 [Internet]. Medellín, Colombia: Secretaría Seccional de Salud y Protección Social de Antioquia; sep 2011 [consultado 2 mar 2022]. Disponible en: https://www.dssa.gov.co/index.php/descargas/881-tamizaje-salud-mental-1/file
Szerman N, Expertos C, Torrens M, Basurte I, Ramírez J, Martínez-Raga J. Patología dual en psicosis. Rev Patol Dua. 2015;2(2):1–4.
Torrens M, Mestre-Pintó JI, Montanari L, Vicente J, Domingo-Salvany A. Patología dual: Una perspectiva europea. Adicciones. 2017;29(1):3–5.
Green AI, Khokhar JY. Addiction and schizophrenia: A translational perspective. Schizophr Res. 2018;194:1–3.
Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234–58.
Matali L, Andion O, Pardo M, Iniesta R, Serrano E, San L. Adolescents and dual diagnosis in a Psychiatric Emergency Service. Adicciones. 2016; 28(2):71–9.
Fonseca-Pedrero E, Lucas-Molina B, Perez-Albeniz A, Inchausti F, Ortuno-Sierra J. Psychotic-like experiences and cannabis use in adolescents from the general population. Adicciones. 2020;32(1):41–52.
Thornton K, Baker L, Lewin J, Kay-Lambkin J, Kavanagh D, Richmond R, et al. Reasons for substance use among people with mental disorders. Addict Behav. 2012;37(4):427–34.
Szerman N, Roncero C, Barral C, Grau-lópez L, Esteve O, Casas M. Patología dual, protocolos de intervención: esquizofrenia. Barcelona: EdikaMed; 2010.
Nielsen SM, Toftdahl NG, Nordentoft M, Hjorthøj C. Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: A nationwide population based register study. Psychol Med. 2017;47(9):1668–77.
Szerman N, Expertos C, Torrens M, Basurte I, Ramírez J, Martínez-Raga J. Dual disorders and psychosis. Rev Patol Dual. 2015;2(2):1-3
Herrera A, Sanyer A. Consumo de sustancias psicotrópicas en pacientes con esquizofrenia en el Hospital Teodoro Maldonado Carbo durante el periodo 2019. 2020 [Tesis de pregrado]. Guayaquil: Universidad Católica de Santiago de Guayaquil; 2020. Recuperado a partir de: http://201.159.223.180/handle/3317/15381
Grau-López L, Szerman N, Torrens M, Basurte I, Vega P, Martínez-Raga J et al. Percepción de los profesionales sobre el uso de la clozapina en pacientes con psicosis dual. Actas Esp Psiquiatr. 2020;48(3):99-105
National Institute of Mental Health. La esquizofrenia [Internet]. NIH; 2017 [consultado 2 mar 2022]. Disponible en: https://www.nimh.nih.gov/health/publications/espanol/la-esquizofrenia/ index.shtm
Cama L. Prevalencia del consumo de sustancias psicoactivas en pacientes diagnosticados con esquizofrenia, Arequipa-2016 [Tesis de pregrado]. Arequipa: Universidad Católica de San Pablo; 2018. Recuperado a partir de: http://54.213.100.250/bitstream/UCSP/15955/1/CCAMA_CALLO_ LIN_SUS.pdf
Sara GE, Large MM, Matheson SL, Burgess PM, Malhi GS, Whiteford HA et al. Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust New Zeal J Psychiatry. 2015;49(2):106–17.
Scheller-Gilkey G, Woolwine B. J, Cooper I, Gay O, Moynes K. A, Miller A.H. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abus. 2003; 29(3):553–66.
Machielsen MW, Veltman DJ, van den Brink W, de Haan L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophr Res. 2018;194: 32–8.
Siskind DJ, Harris M, Phillipou A, Morgan VA, Waterreus A, Galletly C, et al. Clozapine users in Australia: Their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci. 2017;26(3):325–37.
Sepede G, Lorusso M, Spano MC, Di Nanno P, Di Iorio G, Di Giannantonio M. Efficacy and safety of atypical antipsychotics in bipolar disorder with comorbid substance dependence: A systematic review. Clin Neuropharmacol. 2018;41(5):181–91.
Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32(4):637–43.
Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr Opin Psychiatry. 2012;25(3):194–200.
Zhornitsky S, Stip E, Desfossés J, Pampoulova T, Rizkallah É, Rompré PP et al. Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: A 12-week, pilot, case–control trial with quetiapine. Front Psychiatry. 2011;2(22):1-7.
Lícea AG, Robles D, Diaz CX, Juárez J. Trastorno psiquiátrico- esquizofrenia. ESTR [Internet]. 5 de enero de 2019 [consultado 2 mar 2022]; 6(11):34-9. Disponible en: https://repository.uaeh. edu.mx/revistas/index.php/tepexi/article/view/3832
Lähteenvuo M, Batalla A, Luykx JJ, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J et al. Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatr Scand. 2021;144(1):42–9.
Zhou Y, Rosenheck R, Mohamed S, Ning Y, He H. Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge. Psychiatry Res. 2017;250:129–35.
Ahmad I, Khalily MT, Hallahan B. Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort. Asian J Psychiatr. 2017; 30:39–43.